This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Murillo, J. R. Articles by Koeller, J. Search for Related Content PubMed PubMed Citation Articles by Murillo, J. R., Jr. Articles by Koeller, J.

Lung Cancer

Chemotherapy Given Near the End of Life by Community Oncologists for Advanced Non-Small Cell Lung Cancer

^a Methodist Hospital, Houston, Texas, USA; ^b University of Texas at Austin, Austin, Texas, USA; ^c University of Texas Health Science Center, San Antonio, San Antonio, Texas, USA

Correspondence: Jim Koeller, M.S., University of Texas Health Science Center, Medicine—MSC-6220, 7703 Floyd Curl Drive, San Antonio, Texas 78229-3900, USA. Telephone: 210-567-8355; Fax: 210-567-8328; e-mail: koeller{at}uthscsa.edu

Purpose. To characterize the chemotherapy given near the end of life to advanced non-small cell lung cancer (NSCLC) patients treated in the community oncology setting using a medical records database.

Methods. We conducted a retrospective chart review of expired advanced (stage IIIb/IV) NSCLC patients treated with chemotherapy. Patients who initiated chemotherapy in 2000–2003 were eligible. Patient demographics, all chemotherapy including dose and schedule, and disease-related events were collected.

Results. We report data from 10 community practices including 417 patients treated for advanced NSCLC in 2000–2003. The mean age was 67 years (median, 62 years) and 54% were male. Forty percent of patients were >69 years of age and 35% had an Eastern Cooperative Oncology Group performance status score of 2. First-line chemotherapy included combination therapy in 84% of patients. Second-line therapy was given to 56% of patients. Twenty-six percent of patients received third-line therapy, while 10% received fourth-line therapy and 5% received fifth-line therapy or greater. Patients received a mean of 6.1 cycles of chemotherapy. For patients receiving chemotherapy at the time of death, the mean line of therapy being given was second line. Chemotherapy was given within 1 month and 2 weeks of death to 43% and 20% of patients, respectively.

Conclusion. The availability of new chemotherapeutic agents has caused a subsequent increase in the length of time patients are receiving chemotherapy with advanced NSCLC. This would suggest an increased use of chemotherapy near the end of life, which was identified in this study.

This article has been cited by other articles:

				C. C. Earle, M. B. Landrum, J. M. Souza, B. A. Neville, J. C. Weeks, and J. Z. Ayanian Aggressiveness of Cancer Care Near the End of Life: Is It a Quality-of-Care Issue? J. Clin. Oncol., August 10, 2008; 26(23): 3860 - 3866. [Abstract] [Full Text] [PDF]

				S. E. Harrington and T. J. Smith The Role of Chemotherapy at the End of Life: "When Is Enough, Enough?" JAMA, June 11, 2008; 299(22): 2667 - 2678. [Abstract] [Full Text] [PDF]

				G. P. Kalemkerian Guidelines Are Never Enough: A Commentary on "When Guidelines Are Not Enough" J. Clin. Oncol., May 1, 2007; 25(13): 1810 - 1811. [Full Text] [PDF]